Hepion Pharmaceuticals interim CEO Gary Stetz buys $100,000 in stock

On August 3, 2026, Gary S. Stetz, interim CEO and a director at Hepion Pharmaceuticals, Inc., bought $100,000 worth of the company's common stock and warrants. Stetz acquired 2,000,000 shares at $0.05 per share, and 2,000,000 warrants that can be exercised at $0.06 per share. This makes him the owner of 3,250,000 Hepion Pharmaceuticals common shares and 2,000,000 warrants.

The transaction occurred as the stock price was $0.05, down 15% from the previous week. Hepion Pharmaceuticals has a market capitalization of $4.52 million and a beta of 1.65, indicating high volatility. InvestingPro analysts deem the stock overvalued at current levels. During Hepion Pharmaceuticals' 2026 Annual Meeting of Stockholders, Stetz, along with four other directors, was elected to serve until the next annual meeting.

The election was met with significant support, with votes ranging from 13,186,912 to 13,503,469, while having 149,233 to 465,790 votes withheld. Broker non-votes for each nominee amounted to 4,816,704.